All Oncology News

Serial liquid biopsies consistently showed AR alterations linked to poorer outcomes, and findings support “real-time” molecular testing to guide personalized care.

The FDA has granted priority review to the sNDA seeking the approval of belzutifan plus pembrolizumab in ccRCC.

KEYNOTE-B96 showed that pembrolizumab plus paclitaxel improved PFS and OS vs chemotherapy alone in platinum-resistant ovarian cancer.

Induction ipilimumab plus nivolumab followed by consolidative chemoradiotherapy led to bladder preservation in stage 2/3 urothelial carcinoma of the bladder.

Will the FDA approve rusfertide for the treatment of adult patients with polycythemia vera?

The FDA has tentatively approved the abbreviated new drug application for the lutetium lu 177 dotatate radioequivalent PNT2003 in SSTR-positive GEP-NETs.

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Maurie Markman, MD, discusses ethical dilemmas in oncology trials, balancing patient welfare with research integrity and regulatory goals.

A new study suggests that blocking the survival response after PARP inhibitor treatment could bolster their efficacy in ovarian cancer.

The addition of palbociclib to belzuitfan was not associated with improved responses in pretreated clear cell renal cell carcinoma.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

SBRT plus nivolumab and ipilimumab did not improve PFS vs the dual checkpoint inhibitor regimen alone in advanced RCC.

Deep and durable responses were maintained with cabozantinib plus nivolumab in long-term follow-up of the CheckMate 9ER trial.

Pembrolizumab plus belzutifan reduced the risk of having a DFS event by 28% vs pembrolizumab alone in high-risk clear cell RCC.

Belzutifan plus lenvatinib significantly prolonged PFS and showed a trend toward improved OS vs cabozantinib in advanced ccRCC after anti–PD-L1 therapy.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

In SunRISe-2, Gem-iDRS plus cetrelimab did not improve BI-EFS vs chemoradiotherapy in bladder-sparing MIBC and the trial stopped early for futility.

In an OncLive Ask the Expert program, Sagar Lonial, MD, FACP, FASCO, outlined how CELMoDs may be integrated into multiple myeloma care.

February brought key GI cancer updates: FDA approvals in BRAF+ mCRC and pancreatic cancer, plus new fast track and orphan designations.

An analysis of RETAIN-1 and RETAIN-2 showed ctDNA was prognostic for metastatic recurrence in MIBC.

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Roswell Park Comprehensive Cancer Center's Adult Multidisciplinary Neurofibromatosis Clinic was added to the NF Clinic Network.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.